Neuroblastoma – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Neuroblastoma – Pipeline Review, H1 2020’, provides an overview of the Neuroblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Neuroblastoma

– The report reviews pipeline therapeutics for Neuroblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Neuroblastoma therapeutics and enlists all their major and minor projects

– The report assesses Neuroblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Neuroblastoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Neuroblastoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ability Pharmaceuticals SL

Actuate Therapeutics Inc

ADC Therapeutics SA

Advanced Accelerator Applications SA

Alissa Pharma

APEIRON Biologics AG

Aptorum Group Ltd

AstraZeneca Plc

AUM Biosciences Pte Ltd

Autolus Therapeutics Plc

Bayer AG

Bellicum Pharmaceuticals Inc

Bexion Pharmaceuticals LLC

Bio-Cancer Treatment International Ltd

BioEclipse Therapeutics Inc

Biogenera SpA

BioLineRx Ltd

Biotec Pharmacon ASA

BioVec Pharma Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Cancer Prevention Pharmaceuticals Inc

Cebiotex SL

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Chiome Bioscience Inc

Clarity Pharmaceuticals Pty Ltd

Cleveland BioLabs Inc

CorMedix Inc

Curis Inc

Cyclacel Pharmaceuticals Inc

DEKK-TEC Inc

Eli Lilly and Co

Epigene Therapeutics Inc

Epizyme Inc

Errant Gene Therapeutics LLC

EUSA Pharma (UK) Ltd

Expression Therapeutics LLC

F. Hoffmann-La Roche Ltd

GC Pharma

Gibson Oncology LLC

Healx Ltd

Hebei Senlang Biotechnology Inc Ltd

Helixmith Co Ltd

HRAIN Biotechnology Co Ltd

Invenra Inc

Ipsen SA

Jubilant DraxImage Inc

Juno Therapeutics Inc

KC Pharma LLC

Kuur Therapeutics Ltd

Lead Discovery Center GmbH

MacroGenics Inc

Mana Therapeutics Inc

MediaPharma SRL

Merck & Co Inc

Millennium Pharmaceuticals Inc

Nanogenics Ltd

NanoPharmaceuticals LLC

Novartis AG

OGD2 Pharma SAS

Ohara Pharmaceutical Co Ltd

Oncology Venture U.S. Inc

OncoTherapy Science Inc

Ono Pharmaceutical Co Ltd

Open Therapeutics LLC

Orphelia Pharma SAS

Panorama Research Inc

Pfizer Inc

Progenics Pharmaceuticals Inc

Provectus Biopharmaceuticals Inc

PYCTX Ltd

Qualigen Inc

Recombio SL

RedHill Biopharma Ltd

resTORbio Inc

Ribomic Inc

Rophibio Inc

Sapience Therapeutics Inc

SciTech Development LLC

Seneca Therapeutics Inc

Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd

Shionogi & Co Ltd

SignalRx Pharmaceuticals Inc

Sinobioway Cell Therapy Co Ltd

SMTPH Ltd

Sorrento Therapeutics Inc

Tactiva Therapeutics LLC

TheraBiologics Inc

Tmunity Therapeutics Inc

Toko Pharmaceutical Industries Co Ltd

Transtarget Inc

Trellis Bioscience Inc

TroBio Therapeutics Pty Ltd

United Therapeutics Corp

Xcovery Holding Co LLC

Y-Biologics Inc

Y-mAbs Therapeutics Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Introduction

Neuroblastoma - Overview

Neuroblastoma - Therapeutics Development

Neuroblastoma - Therapeutics Assessment

Neuroblastoma - Companies Involved in Therapeutics Development

Neuroblastoma - Drug Profiles

Neuroblastoma - Dormant Projects

Neuroblastoma - Discontinued Products

Neuroblastoma - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Neuroblastoma, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Neuroblastoma – Pipeline by Ability Pharmaceuticals SL, H1 2020

Neuroblastoma – Pipeline by Actuate Therapeutics Inc, H1 2020

Neuroblastoma – Pipeline by ADC Therapeutics SA, H1 2020

Neuroblastoma – Pipeline by Advanced Accelerator Applications SA, H1 2020

Neuroblastoma – Pipeline by Alissa Pharma, H1 2020

Neuroblastoma – Dormant Projects, H1 2020

Neuroblastoma – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Neuroblastoma, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports